Visgeneer Inc., a biotech company, develops and produces biomedical products in the fields of medical device, cosmetics/skin care, bacterial fermentation, and cancer gene identification. More Details
Questionable track record with imperfect balance sheet.
Share Price & News
How has Visgeneer's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4197 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 4197's weekly volatility has decreased from 26% to 5% over the past year.
7 Day Return
TW Medical Equipment
1 Year Return
TW Medical Equipment
Return vs Industry: 4197 exceeded the TW Medical Equipment industry which returned -5.9% over the past year.
Return vs Market: 4197 underperformed the TW Market which returned 48.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Visgeneer's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is Visgeneer undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 4197's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 4197's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 4197 is poor value based on its PE Ratio (730.8x) compared to the TW Medical Equipment industry average (20.1x).
PE vs Market: 4197 is poor value based on its PE Ratio (730.8x) compared to the TW market (17.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4197's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4197's PB Ratio (2x) is in line with the TW Medical Equipment industry average.
How is Visgeneer forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Visgeneer has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Visgeneer performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4197 has a large one-off gain of NT$3.4M impacting its December 31 2020 financial results.
Growing Profit Margin: 4197 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 4197 has become profitable over the past 5 years, growing earnings by -31.6% per year.
Accelerating Growth: 4197 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 4197 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (9.9%).
Return on Equity
High ROE: 4197's Return on Equity (0.3%) is considered low.
How is Visgeneer's financial position?
Financial Position Analysis
Short Term Liabilities: 4197's short term assets (NT$217.9M) exceed its short term liabilities (NT$72.5M).
Long Term Liabilities: 4197's short term assets (NT$217.9M) exceed its long term liabilities (NT$171.5M).
Debt to Equity History and Analysis
Debt Level: 4197's debt to equity ratio (96.3%) is considered high.
Reducing Debt: 4197's debt to equity ratio has increased from 53.9% to 96.3% over the past 5 years.
Debt Coverage: 4197's debt is not well covered by operating cash flow (3.6%).
Interest Coverage: Insufficient data to determine if 4197's interest payments on its debt are well covered by EBIT.
What is Visgeneer current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 4197's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 4197's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 4197's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 4197's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 4197 is not paying a notable dividend for the TW market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 4197's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
Visgeneer has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Visgeneer Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Visgeneer Inc.
- Ticker: 4197
- Exchange: TPEX
- Founded: NaN
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: NT$440.642m
- Shares outstanding: 30.18m
- Website: https://www.visgeneer.com.tw
Number of Employees
- Visgeneer Inc.
- No. 335, Zhonghua Road
- Section 6
- Hsinchu City
Visgeneer Inc., a biotech company, develops and produces biomedical products in the fields of medical device, cosmetics/skin care, bacterial fermentation, and cancer gene identification. The company offers...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/17 08:36|
|End of Day Share Price||2021/06/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.